Navigation Links
TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
Date:2/25/2010

PLEASANTON, Calif., Feb. 25 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

Approximately 12 million Americans are affected by peripheral arterial disease (PAD). Those patients suffer from chronic pain, significant mobility limitations and debilitating quality of life. Left untreated, PAD can lead to a limb loss and even to death.

PAD represents a large unmet clinical need and a critical public health issue. Current balloon and stent therapies suffer from shortcomings in the challenging peripheral environment, evidenced by a low rate of acute and long term success.

"The Glider™ PTA 510K clearance is an important step towards sales of our products in the US market," said Eitan Konstantino, Ph.D., President and Chief Executive Officer of TMI. "This product complements our existing portfolio of Glider™ PTCA and Antares® stent system that are approved and sold in Europe."

An advanced and differentiated product for the PAD therapy market, Glider™ PTA catheters have shaft construction reinforced for torque transmission and an a-traumatic tapered tip configuration. Designed to be delivered through the complex peripheral anatomy to cross long and tight lesions and to restore blood flow in the vessels, Glider™ PTA catheters provide physicians a powerful new tool to treat patients with PAD.

About TriReme Medical, Inc.

Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease.  The Company's novel balloon and stent therapies are specifically designed for large, unmet clinical needs.  

TMI can be contacted at +1 (925) 931-1300 or info@trirememedical.com.

SOURCE TriReme Medical, Inc.

Back to top
'/>"/>
SOURCE TriReme Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
5. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
6. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
9. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
10. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
11. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... (PRWEB) , ... November 13, 2018 , ... Thanks to a generous group of donors, ... offering our supporters and new donors the chance to double their impact with a donation. ... to a total of $700,000. , “In the Sermon on the Mount, Jesus tells his ...
(Date:11/13/2018)... ... November 13, 2018 , ... The best treatment for “tennis elbow,” a ... of the American Journal of Sports Medicine. They say, with time, the condition often ... not necessarily agree with that strategy, at least when it involves injury to the ...
(Date:11/13/2018)... ... November 13, 2018 , ... Grön Matcha, a new Chicago food startup, ... a new generation of tea to consumers via social media. Grön Matcha’s matcha is ... from the Nishio region of Japan, where family farmers have been growing and harvesting ...
Breaking Medicine Technology:
(Date:11/14/2018)... ... ... For what is a first time at the annual iaedp™ Symposium, Adele Lafrance, ... overview of the EFFT model with a focus on supporting research and practical skills ... Next year’s 33rd iaedp™ Symposium is slated for February 7-10, 2019 at the JW ...
(Date:11/14/2018)... , ... November 14, 2018 , ... The Austin-area ... New Year approaches, it’s time to pull out the healthcare plan paperwork to review ... plan or sponsored by an employer, most people can benefit by taking a few ...
(Date:11/13/2018)... FALLS CHURCH, Va. (PRWEB) , ... November 14, ... ... Safety Program to Enforcement Tool, **An FDAnews Webinar**, Nov. 28, 2018 — 1:30 ... is no longer just a safety requirement. It’s now a powerful enforcement tool. ...
(Date:11/13/2018)... ... , ... A survey by the publishers of ADC Review | Journal ... reached U.S. $ 4 billion. Approximately forty-five percent of this market included Antibody-drug Conjugates ... ADCs) is expected to grow significantly, to U.S. $ 17 billion by 2023. [1][2][3] ...
(Date:11/13/2018)... (PRWEB) , ... November 13, 2018 , ... ... the 2019 Medicare Physician Fee Schedule Final Rule and identified seven high volume ... hip arthroplasty) and 27447 (total knee arthroplasty). CMS requested the RUC (Relative Value ...
Breaking Medicine News(10 mins):